Selway Asset Management trimmed its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 10.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 19,650 shares of the biopharmaceutical company’s stock after selling 2,400 shares during the period. Selway Asset Management’s holdings in Gilead Sciences were worth $1,408,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in GILD. BlackRock Inc. boosted its holdings in shares of Gilead Sciences by 1.9% in the second quarter. BlackRock Inc. now owns 104,906,494 shares of the biopharmaceutical company’s stock worth $7,425,281,000 after acquiring an additional 1,937,031 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Gilead Sciences by 2.4% in the second quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock worth $6,571,355,000 after acquiring an additional 2,148,697 shares during the period. FMR LLC boosted its holdings in shares of Gilead Sciences by 1.1% in the second quarter. FMR LLC now owns 23,037,303 shares of the biopharmaceutical company’s stock worth $1,630,581,000 after acquiring an additional 258,005 shares during the period. Northern Trust Corp boosted its holdings in shares of Gilead Sciences by 0.7% in the second quarter. Northern Trust Corp now owns 16,430,476 shares of the biopharmaceutical company’s stock worth $1,162,949,000 after acquiring an additional 116,780 shares during the period. Finally, Franklin Resources Inc. boosted its holdings in shares of Gilead Sciences by 1.0% in the second quarter. Franklin Resources Inc. now owns 14,516,058 shares of the biopharmaceutical company’s stock worth $1,027,436,000 after acquiring an additional 136,884 shares during the period. 76.97% of the stock is owned by institutional investors and hedge funds.
GILD has been the subject of a number of analyst reports. Maxim Group set a $94.00 price target on Gilead Sciences and gave the stock a “buy” rating in a report on Monday, December 11th. Credit Suisse Group reaffirmed a “buy” rating and issued a $82.00 price target on shares of Gilead Sciences in a report on Thursday, December 7th. Vetr lowered Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $90.00 price target for the company. in a report on Wednesday, January 17th. Jefferies Group raised Gilead Sciences from a “hold” rating to a “buy” rating and raised their price target for the stock from $81.19 to $93.00 in a report on Friday, January 26th. Finally, Citigroup raised Gilead Sciences from a “neutral” rating to a “buy” rating and cut their price target for the stock from $88.80 to $76.00 in a report on Tuesday, January 30th. One investment analyst has rated the stock with a sell rating, eleven have assigned a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $87.75.
Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.67 by $0.11. Gilead Sciences had a return on equity of 50.29% and a net margin of 17.73%. The business had revenue of $5.95 billion for the quarter, compared to the consensus estimate of $5.71 billion. During the same quarter last year, the business posted $2.70 earnings per share. The company’s revenue for the quarter was down 18.7% on a year-over-year basis. equities research analysts forecast that Gilead Sciences, Inc. will post 6.21 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Thursday, March 29th. Shareholders of record on Friday, March 16th will be given a dividend of $0.57 per share. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.52. The ex-dividend date is Thursday, March 15th. This represents a $2.28 dividend on an annualized basis and a yield of 2.82%. Gilead Sciences’s dividend payout ratio (DPR) is presently 59.77%.
In other news, CFO Robin L. Washington sold 5,000 shares of Gilead Sciences stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $80.31, for a total value of $401,550.00. Following the transaction, the chief financial officer now owns 23,749 shares in the company, valued at $1,907,282.19. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider John C. Martin sold 50,000 shares of Gilead Sciences stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $73.62, for a total value of $3,681,000.00. Following the completion of the transaction, the insider now owns 3,046,766 shares in the company, valued at approximately $224,302,912.92. The disclosure for this sale can be found here. Insiders have sold 424,435 shares of company stock worth $33,602,330 in the last 90 days. Company insiders own 1.30% of the company’s stock.
WARNING: “Selway Asset Management Trims Holdings in Gilead Sciences, Inc. (GILD)” was originally published by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this report on another website, it was illegally copied and republished in violation of U.S. and international copyright law. The original version of this report can be accessed at https://sportsperspectives.com/2018/03/10/selway-asset-management-trims-holdings-in-gilead-sciences-inc-gild.html.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.